Le Lézard
Classified in: Health
Subjects: NPT, LEG, AVO

Treat and Reduce Obesity Act Gains Support in the U.S. House of Representatives in Record Time


TAMPA, Fla., July 16, 2019 /PRNewswire/ -- The 2019 Treat and Reduce Obesity Act (TROA) (S595) (HR1530) has surpassed 100 co-sponsors in the U.S. House of Representatives with a total of 112 legislators supporting the Act. This critical legislation will provide Medicare beneficiaries with additional tools for weight management and obesity treatment. The bill provides the Centers for Medicare and Medicaid Services (CMS) with the authority to expand the current Medicare benefit to include intensive behavioral counseling by allowing additional types of qualified healthcare providers to offer these services. The Act also allows the agency to expand Medicare Part D coverage to include FDA-approved prescription drugs for chronic weight management.

"Treating obesity and making healthier life choices are goals for many Americans, yet the obesity epidemic continues to plague communities across the country. I am happy to see momentum building for this bipartisan legislation that will help those looking to live a healthier lifestyle achieve their goals, and reduce future health-related costs and complications," said Rep. Ron Kind.

TROA was introduced during the 116th Congress by Senators Bill Cassidy (R-LA) and Tom Carper (D-DE) and Representatives Ron Kind (D-WI), Brett Guthrie (R-KY), Tom Reed (R-NY) and Raul Ruiz, MD (D-CA). It was first introduced during the 113th Congress and again in both the 114th and 115th Congresses where it garnered more than 175 bipartisan supporters each Congress. However, this is the fastest that TROA has reached the 100 milestone?accomplishing it in less than five months' time.  

"We continue to see great momentum with TROA in 2019. More than 93 million adult Americans are living with the disease of obesity. Legislation such as TROA is vitally important for Medicare recipients, as it will provide both healthcare professionals and patients with science-based treatments to address obesity," said Joe Nadglowski, Obesity Action Coalition (OAC) President and CEO.

The OAC encourages all members of the public to advocate for the passage of the 2019 TROA by contacting your legislators by visiting ObesityAction.org/TROA.

The Obesity Action Coalition (OAC), a more than 63,000 member-strong National non-profit organization, is dedicated to improving the lives of individuals affected by the disease of obesity through education, advocacy and support.

SOURCE Obesity Action Coalition


These press releases may also interest you

at 10:02
Boston Institute of Biotechnology, LLC (BIB) in collaboration with BIBo-Biopharma, proudly announces the successful completion of a groundbreaking 30,000L fermentation run, marking a significant milestone in biotechnology history....

at 10:00
Minister Responsible for Relations with the First Nations and the Inuit Ian Lafrenière today submitted in the National Assembly the third annual report on the administration of the Act to authorize the communication of personal information to the...

at 10:00
Cobb Outpatient Detox has opened a new facility in Marietta, GA, providing outpatient drug and alcohol detox services. The center aims to assist individuals in overcoming addiction while balancing their work and family commitments. Located near major...

at 10:00
A new report from the Health Care Cost Institute (HCCI) shows that, even with fluctuations in 2020 and 2021, per person health care spending grew from 2018 to 2022. Over the five years, average prices increased by 14% and utilization went up by about...

at 10:00
BioInnovation Institute (BII), an international non-profit foundation, incubating and accelerating world-class life science research, today announces the launch of the BII & Science Translational Medicine Prize for Innovations in Women´s Health and...

at 10:00
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that the Phase I/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 for multiple advanced solid tumors will be presented...



News published on and distributed by: